Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 191

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 191
---
 early preclinical and clinical stage research programs, which will determine the amount of funding required to further the development of our product candidates; 
 •the progress that we make in developing new product candidates based on our proprietary ProTide technology; 
 •the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop; 
 •the costs involved in filing and prosecuting patent applications and enforcing and defending potential patent claims; 
 •the timing of receipt of our U.K. research and development tax credit cash rebates; 
 •the outcome, timing and cost of regulatory approvals of our ProTide product candidates; 
 

•the cost and timing of establishing sales, marketing and distribution capabilities; and 
 •the costs of hiring additional skilled employees to support our continued growth and the related costs of leasing additional office space. 
 C.  Research and Development, Patents and Licenses, etc.
 Full details of our research and development activities and expenditures are given in “Item 4. Information on the Company–B. Business” and “Item 5A. Operating Results” within this Annual Report.
 D.  Trend Information
 See “Item 5A. Operating Results” within this Annual Report.
 E.  Critical Accounting Estimates
 Not Applicable.
 F. [ Reserved]
 G. [Reserved]
 H. Non-GAAP Financial Measures
 Not Applicable.